FDA Moves Toward Faster Drug Approvals

Follow Drugslib on

By Deanna Neff HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 20, 2026.

via HealthDay

FRIDAY, Feb. 20, 2026 — In a major shift that could fundamentally change how new medicine reaches the pharmacy, the U.S. Food and Drug Administration (FDA) is relaxing a long-standing drug approval requirement for common diseases.

Drugmakers must often complete two separate, large-scale studies to prove a new medication is effective.

Going forward, the FDA’s default position will be to require only one rigorous study for new drugs and other innovative health products.

FDA Commissioner Dr. Marty Makary and his top deputy, Dr. Vinay Prasad, detailed the plan Feb. 18 in The New England Journal of Medicine. The move is the latest in a series of FDA efforts to eliminate hurdles and shorten the timeline for medical reviews.

The requirement for two adequate and well-controlled investigations goes back to the early 1960s. For decades, the second study was designed to be a safety net, confirming that the success of the first trial was not a statistical fluke.

However, FDA leadership now argues that modern science is far more precise.

“In this setting, overreliance on two trials no longer makes sense,” Makary and Prasad wrote, suggesting that the agency has better ways to verify a drug's value today than in the past.

“In 2026 there are powerful alternative ways to feel assured that our products help people live longer or better than requiring manufacturers to test them yet again,” they wrote.

While the new policy marks a significant change for drugs treating common ailments, the FDA has been moving in this direction for years.

Since the 1990s, it has often accepted a single study for treatments targeting rare or deadly diseases where recruiting enough participants for multiple trials is difficult.

About 60% of brand-new drugs approved over the last five years were cleared after one study, according to The Associated Press.

Dr. Janet Woodcock, the FDA's principal deputy commissioner, noted that the new policy will mostly affect medications for common diseases that previously did not qualify for the lower testing hurdles. Regarding cancer and rare disease treatments, Woodcock noted, “The agency has been approving those on a single trial already.”

Despite the shift, FDA officials emphasized that they are not lowering the bar for safety. The agency still retains the authority to demand secondary or even third studies if the initial data is not convincing.

Proponents hope the change will spark a surge in drug development by making it cheaper and faster for companies to get medications to market.

Makary has also directed the agency to shorten FDA reviews in other ways, such as mandating the use of artificial intelligence and offering one-month reviews for some new medications that serve “national interests."

Sources

  • The Associated Press, Feb. 18, 2026
  • The New England Journal of Medicine, Feb. 18, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-02-21 15:58

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords